NCT04789096: Tucatinib Together With Pembrolizumab and Trastuzumab

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Chemotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have previously received Herceptin/trastuzumab, Perjeta/pertuzumab & Kadcyla/T-DM1 in either the neo adjuvant or advanced disease setting
Exclusions: Patients with prior therapy of anti-PD-1, anti- PD-L1/L2 or anti-CTLA4 therapy (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab); Patients with any untreated brain lesions greater than 2.0 cm in size – see trial for details; Patients with leptomeningeal disease

Comments are closed.

Up ↑